Wave Life Sciences/$WVE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Wave Life Sciences
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Ticker
$WVE
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Singapore, Singapore
Employees
288
ISIN
SG9999014716
Website
WVE Metrics
BasicAdvanced
$1.2B
-
-$0.77
-0.92
-
Price and volume
Market cap
$1.2B
Beta
-0.92
52-week high
$15.84
52-week low
$5.04
Average daily volume
1.3M
Financial strength
Current ratio
2.953
Quick ratio
2.782
Long term debt to equity
8.746
Total debt to equity
13.134
Profitability
EBITDA (TTM)
-122.02
Gross margin (TTM)
-59.00%
Net profit margin (TTM)
-107.04%
Operating margin (TTM)
-119.83%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
-30.02%
Return on equity (TTM)
-105.50%
Valuation
Price to revenue (TTM)
11.189
Price to book
7.18
Price to tangible book (TTM)
7.18
Price to free cash flow (TTM)
-6.476
Free cash flow yield (TTM)
-15.44%
Free cash flow per share (TTM)
-123.69%
Growth
Revenue change (TTM)
-7.06%
Earnings per share change (TTM)
40.29%
3-year revenue growth (CAGR)
34.93%
10-year revenue growth (CAGR)
129.40%
3-year earnings per share growth (CAGR)
-29.12%
10-year earnings per share growth (CAGR)
-6.49%
What the Analysts think about WVE
Analyst ratings (Buy, Hold, Sell) for Wave Life Sciences stock.
Bulls say / Bears say
Wave Life Sciences has initiated the INLIGHT clinical trial for WVE-007, targeting obesity through a novel GalNAc-siRNA approach, with clinical data expected in the second half of 2025. (Wave Life Sciences Press Release)
The company achieved the first-ever therapeutic RNA editing in humans with WVE-006 in the RestorAATion-2 trial for Alpha-1 Antitrypsin Deficiency, demonstrating significant increases in wild-type M-AAT protein levels. (Wave Life Sciences Press Release)
Analysts have shown confidence in Wave Life Sciences, with HC Wainwright reiterating a 'Buy' rating and a $22.00 price target, suggesting a potential upside of approximately 95.90% from the current stock price. (Ticker Report)
CEO Paul Bolno sold 169,025 shares of Wave Life Sciences stock in March 2025, which could be perceived negatively by investors. (American Banking and Market News)
The company reported a quarterly loss of $0.47 per share in Q3 2024, missing the Zacks Consensus Estimate of a loss of $0.28, indicating financial challenges. (StockInvest.us)
Wave Life Sciences' projected annual revenue is expected to decrease by 93.26%, raising concerns about the company's financial sustainability. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
WVE Financial Performance
Revenues and expenses
WVE Earnings Performance
Company profitability
WVE News
AllArticlesVideos
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
GlobeNewsWire·4 weeks ago
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Wave Life Sciences stock?
Wave Life Sciences (WVE) has a market cap of $1.2B as of July 18, 2025.
What is the P/E ratio for Wave Life Sciences stock?
The price to earnings (P/E) ratio for Wave Life Sciences (WVE) stock is 0 as of July 18, 2025.
Does Wave Life Sciences stock pay dividends?
No, Wave Life Sciences (WVE) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Wave Life Sciences dividend payment date?
Wave Life Sciences (WVE) stock does not pay dividends to its shareholders.
What is the beta indicator for Wave Life Sciences?
Wave Life Sciences (WVE) has a beta rating of -0.92. This means that it has an inverse relation to market volatility.